Kawasaki Disease
Conditions
Interventions
Administration of sivelestat sodium hydrate
Sponsors
Department of Pediatrics, Chiba University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: We diagnosed Kawasaki disease with the Japanese diagnostic guidelines for Kawasaki disease. Eligible participants are those who remained febrile (37.5 degree Celsius or more of an axillary temperature) 36 to 48 hours after beginning of initial IVIG therapy. Patients who become afebrile within 48 hours after beginning of initial IVIG therapy but become febrile again within day 9 of illness are also considered as refractory to initial IVIG therapy and enrolled in this study.
Exclusion criteria
Exclusion criteria: We excluded patients who become afebrile within 48 hours after beginning of initial IVIG therapy but become febrile again after day 10 of illness, those with concomitant severe medical disorders (eg, immunodeficiency, chromosomal anomalies, congenital heart diseases, metabolic diseases, nephritis, collagen diseases), those with suspected infectious disease, including sepsis, septic meningitis, peritonitis, bacterial pneumonia, varicella, and influenza, those with allergy to some drugs and substances and those who have already been enrolled in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is incidence of coronary artery abnormalities during the study period, which we identified with two-dimensional echocardiography. | — |
Countries
Japan
Contacts
Public ContactRyota Ebata
Chiba University Hospital Department of Pediatrics
Outcome results
None listed